The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

Improve your BCR sequencing analysis with refined IG reference germline sets

May 22, 2024 by Edel Aron

An important aspect of the adaptive immune receptor repertoire analysis is the identification of the V, D, and J genes contributing to the rearranged sequences. Often, the identification of the specific genes requires the use of a reference set of known immune receptor allelic germline variants. Since early meetings of the Adaptive Immune Receptor Repertoire Community (AIRR-C), members of the community have expressed the need to have access to germline sets open to everybody (including industry) that didn’t present known issues in the available germline sets such as different nomenclatures and the requirement of buying licenses. In February 2024, the Germline Database Working Group (GLDB WG) published the manuscript “AIRR-C IG Reference Sets: curated sets of immunoglobulin heavy and light chain germline genes” introducing the AIRR-C human immunoglobulin germline gene reference. This reference is available for download at OGRDB and also available for use in IgBLAST. The AIRR-C IG Reference Sets follow the FAIR principles (Findable, Accessible, Interoperable, and Reusable) and require a minimally restricted licence.

In episode 15 of the On AIRR podcast, Dr. William Lees (researcher at University of London and co-leader of the GLDB WG) and Dr. Corey Watson (associate professor at the University of Louisville) explain in detail the context and expectations of this effort, a major achievement of the group. Watson highlights the impressive effort that it has been for the community to get on the same page, and reach a consensus that could be materialized in these new reference sets, all during a time where the field has matured and evolved in multiple levels. “It has taken us a lot to think how to build a system that is able to accommodate all the elements and also be responsive to changes in the future. We have established a foundation that we can use to build on top of”, Watson says. Good traceability and reproducibility were also requirements from the community. In that sense, Lees explains that “the sets are free to use, can be downloaded through a REST API, they also have a DOI number, so every time a set changes, we create a new DOI, so it is a good reference to put in a paper”.

If you want to learn about the recent innovations and challenges in the generation, curation and analysis of antibody/B-cell and T-cell receptor repertoire data, and in particular in the development and use of germline resources, don’t miss the “AIRR-C Challenge Session: Using IG and TR germline resources for advancing immunobiology” in the upcoming hybrid “AIRR Community Meeting VII – Learnings and Perspectives”.

Filed Under: AIRR Community Tagged With: Adaptive Immune Receptor Repertoire Community

FDA approves IMDELLTRA™ (tarlatamab-dlle) for extensive-stage small cell lung cancer

May 17, 2024 by Janice Reichert

On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted an accelerated approval for IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The approval was based on surrogate endpoints, including response rate and duration of response observed in clinical studies, and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMDELLTRA is bispecific T cell engager (BiTE®, (scFv)2-scFc)) antibody that targets DLL3 on tumor cells and CD3 on the patient’s T cells and has mutations in the Fc (N297G; R292C, V302C) to extend the half-life of the molecules.

FDA’s accelerated approval of IMDELLTRA is based on results from the Phase 2 DeLLphi-301 clinical trial (NCT05060016) that evaluated IMDELLTRA in patients with SCLC who had failed two or more prior lines of treatment, and who had received the 10 mg every two weeks dosing (Q2W) regimen. As reported in the New England Journal of Medicine, results from the study found that IMDELLTRA at the 10 mg Q2W dose demonstrated an objective response rate of 40% and median progression-free survival of 4.9 months. treatment-related adverse events that caused patients discontinuation of tarlatamab treatment occurred in a low percentage (3%) of patients.

IMDELLTRA is currently being evaluated in two Phase 3 studies of SCLC. The Phase 3 DeLLphi-304 study (NCT05740566) is evaluating tarlatamab compared with standard of care in subjects with relapsed SCLC after platinum-based first-line chemotherapy. The Phase 3 DeLLphi-306 study (NCT06117774) is evaluating tarlatamab in subjects with limited-stage SCLC who have not progressed following concurrent chemoradiation therapy. A third Phase 3 study, DeLLphi-305 (NCT06211036), evaluating tarlatamab in combination with durvalumab vs durvalumab alone in subjects with ES-SCLC following platinum, etoposide and durvalumab was not yet recruiting patients as of the last update posted on May 10, 2024.

Details for all approved antibody therapeutics are found in our searchable online table.

Filed Under: Approvals, Food and Drug Administration Tagged With: approved antibodies, Food and Drug Administration, Tarlatamab

Join us for our next webinar on Thursday June 6th!

May 13, 2024 by Janice Reichert

Registration is open!

In this webinar Dr. Jin Lu will show how Lonza’s novel GS Discovery® transient expression platform can boost transient titers by ~30-fold to enable rapid early material supply, and streamline the transition from discovery to stable production. Dr. Lu will also introduce bYlok® bispecific pairing technology – an innovative solution that drives correct heavy-light chain pairing rates in IgG-like bispecifics to >95%. This improves yields of the correct species and streamlines downstream processing, without affecting key performance attributes of the molecule. Dr. Lu will present the latest case studies of bYlok® engineered bispecifics and explore how bYlok® compares to other established pairing solutions.

Filed Under: Bispecific antibodies Tagged With: antibody discovery, bispecific, Webinar

Registration Reminder for AIRR-C Meeting VII!

May 9, 2024 by Edel Aron

Register for AIRR-C Meeting VII! Once registered, remember to sign up for the workshops and tutorials through the Whova meeting app. Also, if you haven’t already, be sure to sign up for the fabulous Cálem Port Wine Cellars Tour & Group Dinner. Tickets are almost sold out!

We now also have some striking t-shirts available for purchase in our Porto collection.

Filed Under: AIRR Community Tagged With: Adaptive Immune Receptor Repertoire Community, Meetings

2024 Research Competition winners!

May 3, 2024 by Silvia Crescioli

The Society’s Communication and Membership Committee is glad to announce the 2024 Research Competition winners! 

 

Our student winner is:

Ms. Marlena Surówka (Roche Innovation Center Zurich, Ludwig Maximilian University of Munich)

Poster title: P329G-Engager: A Novel Universal Antibody-based Adaptor Platform For Cancer Immunotherapy

 

Our post doc winner is:

Dr. Shivani Sachdev (National Institutes of Health (NIH))

Poster title: Leveraging antibodies and chemistry to interrogate cell surface receptor function

 

The Antibody Society sponsors competitions each year to recognize and encourage the research activities of promising student/postdoctoral fellows. For the Research Competition, participants submitted a summary of their work on a topic related to antibody research. Winners (1 student and 1 post-doc) were selected based on originality, creativity, scientific merit, clarity of their research and its presentation.

Winners will receive:

  • broad exposure of their work,
  • a $400 cash prize,
  • and the option of a free registration to: 1) Schrödinger’s online course, Introduction to Computational Antibody Engineering; or 2) virtual Antibody Engineering & Therapeutics.

Congratulations to our winners and thanks to everyone who participated!

Watch out for our next Research Competition in 2025!

Information on past competitions and winners can be found here.

Filed Under: Competition, Uncategorized Tagged With: antibody discovery, antibody engineering, competition

« Previous Page
Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III — A Milestone Virtual Gathering! June 3, 2025
  • Register now for the June 26th AIRR Community Seminar Series June 3, 2025
  • Zooming into the Community III Starts Tomorrow! May 20, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals